EOCN EoCene Ltd.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1595353 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026-06-30), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-30.1%
TTM EPS YoY-182.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-68.2%
ROA-55.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets30.3%
Debt / equity0.00x
Current ratio4.16x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $4.87M | $2.98M |
| SG&A expense | $3.64M | $3.30M |
| Pretax income | — | $7.52M |
| Income tax | $0 | — |
| Net income | -$10.31M | -$7.52M |
| EPS (basic) | 2.39 | 8.08 |
| EPS (diluted) | 2.39 | 8.08 |
| Weighted avg. shares (diluted) | 4.31M | 930,822 |
| Balance sheet | ||
| Cash & equivalents | $3.98M | $4.65M |
| Short-term investments | $7.03M | $7.18M |
| Receivables | — | $672,000 |
| Current assets | $18.63M | $16.12M |
| Total assets | $18.63M | $18.50M |
| Current liabilities | $2.85M | $2.17M |
| Total liabilities | $2.85M | $2.17M |
| Shareholders' equity | $15.78M | $16.33M |
| Shares outstanding | 822,674 | 1.66M |
| Cash flow statement | ||
| Operating cash flow | -$6.32M | -$5.88M |
| Investing cash flow | -$3.38M | -$1.11M |
| Financing cash flow | $9.03M | $8.79M |
| Depreciation & amortization | — | $83,000 |
| Stock-based compensation | $546,000 | $531,000 |
Free plan shows the latest 2 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.